\n\n\n\n\t\t\n\t\t\tLeptos Biomedical\n\t\t\thttp://www.leptosbiomedical.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tLeptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the...More»
\n\t\t\tLeptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system.
We believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use.«Less
Overview
\n\t\t\t\tLocation: \tBrooklyn Center, MN, United States\n
\n\t\t\t\tIndustry: Medical Devices & Equipment
\n\t\t\t\tTags:\n\t\t\t\tobesity,\n\t\t\t\tneuromodulation therapy,\n\t\t\t\tleptos,\n\t\t\t\tfat,\n\t\t\t\tLeptos biomedical\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series C - $20M (08/2007)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tLatterell Venture Partners,\n\t\t\t\t\t\n\t\tSpray Venture Partners,\n\t\t\t\t\t\n\t\tThomas McNerney & Partners,\n\t\t\t\t\t\n\t\tTechnology Partners.\n\t\t\t\t
\n\t\t\tMarket
\n\t\t\t\tCompetitors:\n\t\t\t\t\t\tReShape Medical\n\t\t\t\t
\n\n\t\t\t